Co-Diagnostics Files Definitive Proxy Statement

TL;DR

CDXC proxy statement is out - shareholders vote on leadership & strategy.

AI Summary

Co-Diagnostics, Inc. filed its definitive proxy statement on July 16, 2024, for its annual meeting of shareholders. The filing outlines the company's governance and proposals to be voted on by shareholders. Key details regarding executive compensation, director elections, and other corporate matters are expected to be detailed within the full proxy statement.

Why It Matters

This filing provides shareholders with crucial information to make informed voting decisions on company leadership and strategic direction.

Risk Assessment

Risk Level: medium — Proxy statements can reveal important information about executive compensation, board composition, and shareholder proposals that may impact the company's future performance and stock price.

Key Players & Entities

• Co-Diagnostics, Inc. (company) — Registrant
• July 16, 2024 (date) — Filing Date
• 4049 SOUTH HIGHLAND DRIVE (address) — Company Business Address
• SALT LAKE CITY (location) — Company City
• UT (state) — Company State
• 84124 (zip_code) — Company Zip Code
• 8012789769 (phone_number) — Company Phone Number

FAQ

Key Financial Figures

• $0.001 — g furnished to holders of common stock, $0.001 par value per share, of Co-Diagnostics,

Filing Documents

• formdef14a.htm (DEF 14A) — 350KB
• logo_001.jpg (GRAPHIC) — 18KB
• formdef14a_001.jpg (GRAPHIC) — 60KB
• formdef14a_002.jpg (GRAPHIC) — 58KB
• proxy_001.jpg (GRAPHIC) — 176KB
• proxy_002.jpg (GRAPHIC) — 160KB
• 0001493152-24-028019.txt ( ) — 1002KB

From the Filing

DEF 14A 1 formdef14a.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under §240.14a-12 CO-DIAGNOSTICS, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. CO-DIAGNOSTICS, INC. 2401 S. Foothill Drive, Suite D Salt Lake City, Utah 84109 (801) 438-1036 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held Virtually at 10:00 A.M. (Mountain Time) on Thursday, August 29, 2024 NOTICE IS HEREBY GIVEN that the virtual-only Annual Meeting of Shareholders (the “Annual Meeting”) of Co-Diagnostics, Inc., a Utah corporation (“we” or the “Company”), will be held on August 29, 2024 at 10:00 A.M. (Mountain Time), on a virtual basis, for the following purposes, all of which are discussed in greater detail in the accompanying proxy statement: 1. To elect one (1) Class III director nominee, who is currently serving on our board of directors, to serve until the 2027 annual meeting of shareholders or until his successor is duly elected and qualified, or until his earlier death, resignation, or removal; 2. To adopt, on an advisory basis, the compensation of the Company’s named executive officers; 3. To vote, on an advisory basis, on the frequency of future advisory votes to approve the compensation of the Company’s named executive officers; 4. To ratify the appointment of Tanner LLC as our independent registered public accounting firm for the fiscal year ending December 31, 2024; and 5. To transact such other business as may properly come before the meeting or any adjournment thereof. Only those shareholders of record as of the close of business on July 5, 2024, the record date for the Annual Meeting (the “Record Date”), will be entitled to vote at the Annual Meeting and any adjournments or postponements thereof. The Annual Meeting will be a completely virtual meeting of shareholders, which will be conducted via live webcast. You will be able to attend the Annual Meeting online, vote and submit your questions during the Annual Meeting by visiting www.virtualshareholdermeeting.com/CODX2024 . We are pleased to utilize the virtual shareholder meeting technology to provide ready access and cost savings for our shareholders and the Company. The virtual meeting format allows attendance from any location in the world. Even if you are planning on attending the Annual Meeting online, please promptly submit your proxy vote via the Internet, by telephone, or, if you received a printed form of proxy in the mail, by completing, dating, signing and returning the enclosed proxy, so your shares will be represented at the Annual Meeting. Instructions on voting your shares are on the proxy materials you received for the Annual Meeting. Even if you plan to attend the Annual Meeting online, it is strongly recommended you vote before the Annual Meeting date, to ensure that your shares will be represented at the Annual Meeting if you are unable to attend. i You may revoke your proxy at any time prior to the Annual Meeting. If you attend the Annual Meeting and vote by ballot, your proxy will be revoked automatically and only your vote at the Annual Meeting will be counted. If your shares are held in the name of a bank, broker, or other holder of record, you must obtain a proxy, executed in your favor, from the holder of record in order to be able to vote in person at the Annual Meeting. Details regarding admission to the meeting and the business to be conducted at the meeting are more fully described in this Notice of Annual Meeting of Shareholders and accompanying proxy statement. OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR” EACH OF THE PROPOSALS. The proxy statement accompanying this notice provides a more complete description of the business to be conducted at the Annual Meeting. We encourage you to read the proxy statement carefully and in its entirety. BY ORDER OF THE BOARD OF DIRECTORS, /s/ Dwight H. Egan Chairman of the Board and Chief Executive Officer Salt Lake City, Utah July 16, 2024 This Notice of Annual Meeting of Shareholders, proxy statement and form of proxy are first being mailed to shareholders on or about July 16, 2024. Important Notice Regarding the Availability of Proxy Materials for the C

View Full Filing

View this DEF 14A filing on SEC EDGAR